Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Takeda Pharmaceutical Company (TAK)

Tipranks - Tipranks - Wed Apr 1, 3:12AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allogene Therapeutics (ALLO) and Takeda Pharmaceutical Company (TAK) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Allogene Therapeutics (ALLO)

TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Allogene Therapeutics today. The company’s shares closed last Monday at $2.22.

According to TipRanks.com, Buren is a 5-star analyst with an average return of 20.6% and a 53.9% success rate. Buren covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., NewAmsterdam Pharma Company, and Crinetics Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics with a $8.71 average price target, implying a 288.5% upside from current levels. In a report issued on March 20, Canaccord Genuity also maintained a Buy rating on the stock with a $14.00 price target.

See the top stocks recommended by analysts >>

Takeda Pharmaceutical Company (TAK)

In a report released yesterday, Michael Nedelcovych from TD Cowen maintained a Buy rating on Takeda Pharmaceutical Company, with a price target of $21.00. The company’s shares closed last Monday at $18.27.

According to TipRanks.com, Nedelcovych is a 1-star analyst with an average return of -4.5% and a 42.1% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Molecular Partners AG, and Coherus Biosciences. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Takeda Pharmaceutical Company with a $18.00 average price target.

Read More on ALLO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).